Primary safety endpoint: Number of at least possibly related Grade 3 adverse events (AE) and serious adverse events (SAE) from time of first administration of ABNCoV2 until the end of the follow-up period.Primary immunogenicity endpoint: Concentration of ABNCoV2-specific antibodies 14 days following first vaccination.

Primary safety endpoint: Number of at least possibly related Grade 3 adverse events (AE) and serious adverse events (SAE) from time of first administration of ABNCoV2 until the end of the follow-up period.Primary immunogenicity endpoint: Concentration of ABNCoV2-specific antibodies 14 days following first vaccination.